Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion

Japanese Journal of Ophthalmology

Volumn 59, Issue 6, 2015, Pages 389-393

  Yamada, Rika ^a,b   Nishida, Akihiro ^a,b   Shimozono, Masataka ^a,b   Kameda, Takanori ^a,b   Miyamoto, Noriko ^a,b   Mandai, Michiko ^a,c   Kurimoto, Yasuo ^a,b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

Bevacizumab; Branch retinal vein occlusion; Macular edema; Recurrence

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA ISCHEMIA; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; RISK FACTOR;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECURRENCE; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947490023     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-015-0412-2     Document Type: Article

References (29)

1. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33:901–10.
2. Recupero SM, Perdicchi A, Scuderi GL, Amodeo S, Medori EM, Leonardi A. Visual acuity in central and branch vein retinal occlusion in the presence of macular edema: 1 year of follow-up. Ann Ophthalmol (Skokie). 2006;38:107–10.
3. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–9.
4. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249:183–92.
5. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal bevacizumab (avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452–6.
6. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–60.
7. Scott IU, Vanveldhuisen PC, Oden NL, Ip MS, Domalpally A, Doft BH, et al. Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14. Arch Ophthalmol. 2012;130:1517–24.
8. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–82.
9. Charbonnel J, Glacet-Bernard A, Korobelnik JF, Nyouma-Moune E, Pournaras CJ, Colin J, et al. Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol. 2004;242:223–8.
10. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol. 1999;97:465–9.
11. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56:165–74.
12. Yasuda S, Kondo M, Kachi S, Ito Y, Terui T, Ueno S, et al. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion. Retina. 2011;31:1075–82.
13. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2008;246:1241–7.
14. Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, Park KH, et al. Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study. Jpn J Ophthalmol. 2014;58:146–54.
15. Terao R, Yuda K, Kure K, Inoue T, Ohtsu H, Yanagi Y. Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol. 2014;58:139–45.
16. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol. 2008;126:513–8.
17. Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92:1316–9.
18. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111–31.
19. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120:795–802.
20. Manaviat MR, Rashidi M, Afkhami-Ardekani M, Mohiti-Ardekani J, Bandala-Sanchez M. Effect of pan retinal photocoagulation on the serum levels of vascular endothelial growth factor in diabetic patients. Int Ophthalmol. 2011;31:271–5.
21. Mohamed TA. Mohamed Sel D. Effect of pan-retinal laser photocoagulation on plasma VEGF, endothelin-1 and nitric oxide in PDR. International. J ophthalmol. 2010;3:19–22.
22. Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica. 2011;226:145–50.
23. Lyall DA, Tey A, Foot B, Roxburgh ST, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26:1517–26.
24. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31:654–61.
25. Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70–5.
26. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, Murray TG, et al. Endophthalmitis after intravitreal vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31:662–8.
27. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118:2028–34.
28. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–7.
29. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol. 2013;156:693–705.